J. Silverfield

发表

FV‐100 versus valacyclovir for the prevention of post‐herpetic neuralgia and the treatment of acute herpes zoster‐associated pain: A randomized‐controlled trial

S. Tyring, A. Moore, Patricia C. Lee, 2016, Journal of medical virology.

2.5 Rheumatoid arthritis – non biologic treatment

H. Valdez, H. Nakamura, S. Zwillich, 2012 .

Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac.

D. Furst, R. Fleischmann, M. Greenwald, 2002, The Journal of rheumatology.

Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone.

M. Miller, W. Blackburn, R. Gordon, 1995, Arthritis and rheumatism.

Rheumatoid vasculitis: survival and associated risk factors.

D. Ballard, D. Ilstrup, J. Silverfield, 1986, Medicine.

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

R. Moots, P. Emery, D. Mevorach, 2017, The Lancet.

Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study.

Shu-chen Wu, N. Rosenthal, M. Kamin, 2002, Clinical therapeutics.

TENIDAP IN RHEUMATOID ARTHRITIS

Michael J. Miller, W. Blackburn, R. Gordon, 2005 .

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

E. Lee, J. Gómez-Reino, C. Bingham, 2015, Annals of the rheumatic diseases.

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies

E. Lee, C. Nduaka, J. Curtis, 2014, The Journal of Rheumatology.

SAT0234 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years

J. Wollenhaupt, J. Silverfield, S. Strengholt, 2015, Saturday, 16 JUNE 2018.

Immunochemical properties of human low density lipoproteins as explored by monoclonal antibodies. Binding characteristics distinct from those of conventional serum antibodies.

M. Alley, C. Fathman, S. Mao, 1982, Biochimica et biophysica acta.

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Stanley B. Cohen, J. Curtis, J. Wollenhaupt, 2019, Arthritis Research & Therapy.

Intra-articular orgotein in osteoarthritis of the knee: a placebo-controlled efficacy, safety, and dosage comparison.

J. Silverfield, D. E. Cheatum, H. Mcilwain, 1989, The American journal of medicine.

Comparison of Tripterygium wilfordii Hook F Versus Sulfasalazine in the Treatment of Rheumatoid Arthritis

P. Lipsky, G. Csako, R. Wesley, 2009, Annals of Internal Medicine.

Tramadol/Acetaminophen Combination Tablets for the Treatment of Pain Associated with Osteoarthritis Flare in an Elderly Patient Population

Shu-chen Wu, N. Rosenthal, M. Kamin, 2004, Journal of the American Geriatrics Society.

T‐Lymphocyte Subsets During Pregnancy and the Menstrual Cycle

C. Fathman, C. Coulam, J. Silverfield, 1983, American journal of reproductive immunology : AJRI : official journal of the American Society for the Immunology of Reproduction and the International Coordination Committee for Immunology of Reproduction.

THU0179 Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-label, Long-term Extension up to 6 Years

A. Anisfeld, H. Nakamura, J. Wollenhaupt, 2015 .

Rheumatoid Vasculities: Survival and Associated Risk Factors

D. Ballard, D. Ilstrup, J. Silverfield, 1986, Medicine.